ERA 2026: HighTide Therapeutics Presents Latest Research Findings on HTD1801's Renal Protection in Oral Presentation
ERA 2026: Haisco Pharmaceutical Presents Latest Kidney Protection Research Results of HTD1801 in Oral Presentation
Haisco Pharmaceutical ($HIGHTIDE-B(02511.HK)), an innovative biopharmaceutical company focused on cardiorenal metabolic (CKM) diseases and developing multi-functional, multi-targeted therapies, today presented the latest kidney protection research results of its core product HTD1801 in an oral presentation at the 63rd European Renal Association (ERA) Congress held in Glasgow, UK.
HTD1801 is a first-in-class anti-inflammatory metabolic modulator (AIMM) targeting the AMPK-NLRP3 pathway. In the completed Phase III clinical studies (SYMPHONY-1&2), HTD1801 significantly improved renal function in patients with type 2 diabetes (T2DM) whose baseline eGFR was 60–90 mL/min/1.73m². After 52 weeks of treatment, the eGFR of these patients increased by an average of +3.08 mL/min/1.73m² (95% CI: 0.46–5.70), with no occurrence of hyperfiltration or fluid retention. These results suggest that HTD1801 has differentiated advantages over existing mechanism drugs and possesses the potential to delay or even reverse disease progression.
This study further explains the aforementioned clinical results. Conducted jointly by Haisco Pharmaceutical and the research team of Academician Jiang Jiandong from the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, the results show that in glucose and palmitic acid-induced podocyte injury models, HTD1801 can significantly increase podocyte survival rate and inhibit apoptosis; restore the expression of key podocyte structural proteins nephrin and podocin; and significantly reduce the levels of phosphorylated NF-κB in the metabolic inflammation pathway and the apoptosis execution protein caspase-3. In a diabetic nephropathy (DN) model, HTD1801 improved renal tissue structure in a dose-dependent manner, reduced the renal tubular injury score, alleviated renal inflammation and fibrosis lesions, and significantly lowered 24-hour urinary microalbumin levels.
This study systematically elucidates that HTD1801 can inhibit podocyte inflammation and apoptosis, stabilize glomerular structure, further revealing the kidney protection potential of HTD1801, providing important scientific evidence for its potential as a therapy for chronic kidney disease (CKD) and other kidney diseases.
Abstract Title: HTD1801 Alleviates Podocyte Apoptosis and Glomerular Injury -- An Exploration of Kidney Protection Mechanisms
Presentation Number: 2243
Presentation Time: Thursday, June 4, 2026, 08:15 AM (BST)
Presentation Format: Oral Presentation
Presenter: Dr. Filip Surmont, Chief Medical Officer of Haisco Pharmaceutical
Dr. Filip Surmont, Chief Medical Officer of Haisco Pharmaceutical, stated: "This study is the first to reveal the kidney-protective effects of HTD1801 at the podocyte and glomerular levels. The high consistency between clinical and preclinical research results further confirms HTD1801's ability to target the core pathological processes in CKD or other kidney diseases, highlighting its significant therapeutic potential. We will continue to advance the clinical development of HTD1801 in indications such as CKD, striving to bring more innovative treatment options to kidney disease patients worldwide."
About HTD1801
HTD1801 is a first-in-class new molecular entity designed to address the unmet clinical needs of cardiorenal metabolic (CKM) diseases. As a single molecule, HTD1801 is an oral anti-inflammatory and metabolic modulator (AIMM) with a unique dual mechanism of action, exerting its biological activity by activating AMPK and inhibiting the NLRP3 inflammasome; this complementary and synergistic dual mechanism can effectively address metabolic issues. Multiple global clinical results have verified that HTD1801 possesses the characteristic of "one drug, multiple effects," capable of providing patients with comprehensive benefits, including improved insulin sensitivity, glycemic control, lipid reduction, kidney protection, weight loss, liver benefits, and anti-inflammatory effects. Based on this, HTD1801 has the potential to become a foundational treatment in the CKM field.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
